Pilot Phase Sample Clauses

Pilot Phase. During the period of performance of the Joint Development Program (the “Pilot Phase”), the objective is to demonstrate the ability to manufacture Bio-BDO via the Bioprocess using cellulosic sugars generated from Biomass feedstocks via the PROESA™ Process Technology in the Pilot Plant Facility. The principal tasks in the Pilot Phase shall consist of those matters set forth in the Development Plan.

Pilot Phase. (a) During the Pilot Phase, the responsibility of the Parties for costs and expenses will be as set forth in Schedule 3.1(a). Without the approval of the JDC, neither Party will incur any capital expenditures in the performance of the Pilot Phase except as expressly set forth in the Development Plan. (b) […***…]. The JDC will determine whether the technical and commercial key performance indexes (KPIs) for the Pilot Phase, as set forth in the Development Plan (the “Commercialization KPIs”) have been satisfied. The Pilot Phase will continue until the date that the principal tasks in the Development Plan (and any other tasks reasonably determined by Genomatica) have been completed, whether or not the Commercialization KPIs have been satisfied.

Pilot Phase. (1) Upon completion of the Analytical Phase Sandoz shall implement the Process in its facilities and Manufacture the Pilot Batches of the API, although not necessarily in compliance with the API Specifications, for the purpose of qualifying the Process. In accordance with the Technology Transfer Plan, the Pilot Phase shall run for a minimum of **) **, with the actual number of total ** to be agreed upon by Unigene and Sandoz based on the results of the Pilot Phase. The parties acknowledge that Sandoz’s ability to conduct the Pilot Phase in accordance with this timetable is dependent on timely delivery by Unigene in accordance with the Technology Transfer Plan of agreed-upon Process Transfer Information. The parties agree to use their commercially reasonable endeavors to ensure that the timeline for the Pilot Phase is met. (2) If during the Pilot Phase the parties identify an unforeseeable technical problem, which prevents Sandoz from Manufacturing the Pilot Phase Batches, then the following procedure shall apply: (a) Sandoz may request further reasonable technical assistance from Unigene and Unigene shall according to Clause 4(8)(a)provide technical assistance as reasonably deemed appropriate by Sandoz. (b) Sandoz shall use its commercially reasonable endeavors to resolve the problem to both parties’ satisfaction and Unigene shall be entitled to have a representative present at the Sandoz site and to fully participate in solving such problem to ensure that this provision is satisfied. (3) If the parties are unable to resolve the problem in the manner described in Clause 3(2)(b) and are not progressing to a mutually agreeable resolution of the problem within a minimum of **) weeks of identification thereof, then Sandoz may terminate this Agreement, in which case the parties’ obligations hereunder shall terminate, other than each party’s obligation of confidentiality and to return the other party’s Confidential Information. (4) Subject to completion of the Pilot Phase, Sandoz will conduct the Demonstration Lot Campaign, and will deliver the Product produced therefrom to Novartis Pharma AG upon completion of such campaign. The parties agree that the Demonstration Lot Campaign means that Sandoz shall Manufacture (a) up to ** Engineering Batches of API and (b) ** cGMP Batches of API that meet the API Specifications, within the timeline stated in Clauses 9(1)(c) and 11(1). If during the Demonstration Lot Campaign the parties identify an unforeseeable technical p...

Pilot Phase. There were two phases of piloting. The first phase was carried out to assess whether the trauma films in the acquisition phase produced the conditioned fear response according to SCR amplitude and subjective ratings. Changes were then made to the protocol and the second piloting phase was completed to further assess whether the stimuli were producing the conditioned fear response and to assess the feasibility of the design. The pilot participants were recruited via email and were all staff or students at King’s College London. They all met inclusion criteria for the study and gave written informed consent. Four participants completed the first phase of piloting. 50% of these participants did not meet minimum response criteria for the conditioned SCR. The mean age of these participants was 27 (SD=1.73) and three of these participants were female and one was male. The intensive presentation phase was added to the protocol to attempt to produce a more consistent conditioned response. Nine participants (three per group) completed the second phase of piloting. The mean age of these participants was 27.5 (SD=2.69), eight participants were female and one was male. Eight participants (88%) showed a conditioned SCR above minimum criteria. All participants reported an increase in subjective ratings of distress to the CS+ after viewing the trauma films. The main aim of the piloting stage was to assess whether the stimuli produced the conditioned fear response at acquisition according to SCR and subjective distress ratings. SCR was inspected visually and 10 out of the 13 pilot participants had produced an SCR amplitude of greater than 0.02µs in response to the unreinforced CS+. Eight out of nine participants in the second phase acquired the conditioned fear response according to this criterion, which was after the addition of the intensive presentation phase. For the participants who also viewed the CS- following conditioning (n=6), there was a significant difference between subjective distress ratings to the CS+ (mean=56.67, SD=23.38) and the CS- (mean=0, SD=0) following

Pilot Phase. After training is complete, the project team will schedule a follow up session within 5 business days of setup. The purpose of this session is to review the recommendations made by the tool and assess the impact in terms of savings for the customer. The pilot phase encourages the team to begin using the system. This phase will last 2 weeks during which Aurea's business consultants will be available for a 1-hour question and answer session. Recordings of these sessions will be provided to the customer for future reference.

Pilot Phase. The Pilot Phase will involve defined group/s of SEIU 521 represented workers/Supervisors and management teams, as determined in the Design Phase, implementing the proposed operational model/s for a set period of time. During the Pilot Phase there will be regular check-ins, which will include iterative fine tuning, gathering data, and recognizing best practices and lessons learned. The Pilot Phase will continue for up to one (1) year.

Pilot Phase. During the pre-pilot phase the outreach events should be focused on showing the new concept to interested stakeholders and communication and social media. Our strategy involves using social networks and blogs to make people aware of SoCaTel. The activities to be carried out in this phase are: Considering that journalists are flooded with potential stories and pitches on a daily basis, making SoCaTel stand out is crucial. While the format for a press release is basic, the content of the release should be anything but. We follow the tips outlined below to write a great press release that shows that our organization is professional, accessible, and attractive to writers looking for stories. • Place press release on letterhead. • List official contact person and mobile phone number as well as your contact information. A common oversight that can render a press release ineffectual is a lack of contact information for reporters to follow up on. • In a press release, it is customary to indicate at the top whether the press release is for immediate release or to be kept until a certain date, which is a request that the information or news provided by the source not be published until a certain date or certain conditions have been met. • Grab attention with a good headline. The introduction of a press release is the most important. A strong headline will pull in journalists seeking good stories. • Get right to the point in the first paragraph. Reporters are busy people. We must assume that they will only read the first sentence and then scan the rest – and even that is a generous assumption. Every important point should be addressed in the first few sentences. The subsequent paragraphs should be for the “Who, What, Where, When, Why & How” supporting information. • Using quotes to draw the attention of journalists and media figures. Using quotes also gives it a personal touch or voice.

Pilot Phase. The Program will commence with a pilot phase ("Pilot Phase") for the deployment of the Cymedix Software with the Pilot Providers. The objective of the Pilot Phase is to establish an electronic communication link between the Pilot Providers and Kaiser or its designated Plan TPA, enabling Kaiser to evaluate the viability of the link and the functionality of the Cymedix Software. The applications available to Pilot Providers during the Pilot Phase shall be limited to the following Healthcare Transactions (collectively, "Pilot Transactions"): (a) Claim Submissions; (b) Claim Acknowledgements; and (c) Eligibility Transactions to the extent included in the Implementation Plan.

Pilot Phase. (1) Not later than * weeks in advance of commencing the Pilot Phase for a Product, Celltech shall supply and transfer to Biochemie all remaining Process Transfer Information that is reasonably required for Biochemie to Manufacture and deliver Product. (2) Upon completion of the Analytical Phase (unless otherwise determined by Celltech as stated in Clause 5(5) and subject to prior agreement by the parties of the Pilot Phase Protocol, Biochemie shall implement the Process in its facilities and Manufacture the Pilot Batches of Product, although not necessarily in compliance with Product Specifications, for the purpose of qualifying the Process. Biochemie will conduct all such activities only at its facilities located in Austria. The Pilot Phase shall run for an estimated period of * weeks, with the actual number of total weeks to be agreed upon by Celltech and Biochemie based on the results of the Pilot Phase. The parties acknowledge that Biochemie’s ability to conduct the Pilot Phase in accordance with this timetable is dependant on timely delivery (not later than * weeks in advance of commencing the Pilot Phase) by Celltech of agreed-upon Process Transfer Information and timely completion by Biochemie of the Analytical Phase. The parties agree to use their best endeavours to ensure that the timelines for the Analytical and Pilot Phases are met. (3) If during the Pilot Phase the parties identify an unforeseeable technical problem which prevents Biochemie from Manufacturing the Pilot Phase Batches, then the following procedure shall apply: (a) Biochemie may request further reasonable technical assistance from Celltech. (b) Biochemie shall use its best endeavors to resolve the problem to both parties’ satisfaction and Celltech shall be entitled to have a representative present at the Biochemie site and to fully participate in solving such problem to ensure that this provision is satisfied. (c) Save as provided in sub-Clause (3)(d) below, the additional cost of resolving the problem shall be borne by the party who is responsible for the problem, as mutually agreed by the parties, and if both parties are responsible then the cost shall be borne by both parties proportionally to the level of their respective fault. (d) If Pilot Phase was started before completion of the Analytical Phase at the direction of Celltech and the problem is a direct consequence of non-completion of the Analytical Phase, then the additional cost of resolving the problem shall be borne * ...

Pilot Phase. During the initial period of performance of the Joint Development Program (the “Pilot Phase”), the objective is to demonstrate the ability to manufacture Carbon Nanotubes and Hydrogen using NMT’s THERMO-CVD Process Technology in the Pilot Plant Facility. The principal tasks in the Pilot Phase shall consist of those matters set forth in the Development Plan. (a) During the Pilot Phase, the responsibility of the Parties for the Joint Development Program will be as set forth in the Development Plan. Without the approval of the JDC, neither Party will incur any capital expenditures in the performance of the Pilot Phase except as expressly set forth in the Development Plan. (b) The JDC will determine whether the technical and commercial key performance indexes (KPIs) for the Pilot Phase, as set forth in the Development Plan (the “Joint Milestones”) have been satisfied. The Pilot Phase will continue until the date that the principal tasks in the Development Plan (and any other tasks reasonably determined by the JDC) have been completed, whether or not the Commercialization KPIs have been satisfied.